Companies › Sound Biopharmaceuticals
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| FTL008.16 | – | Phase 1 | Solid Tumors | Nov 2026 |
| FTL001 | – | Phase 1 | Solid Tumor | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06410131 | FTL008.16 | Phase 1 | Solid Tumors | Oncology | Nov 2026 |
| NCT06410092 | FTL001 | Phase 1 | Solid Tumor | Oncology | Mar 2027 |
Cash of 655m CNY on 2025-12-31; operating cash flow positive
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.